Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21
Clinical trial NCT01714908 · UNKNOWN
Trial details
- NCT number
- NCT01714908
- Sponsor
- Jinming Yu
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-12-14
- Primary completion
- 2018-08-20
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.